Axitinib plus avelumab in the treatment of recurrent glioblastoma: a stratified, open-label, single-center phase 2 clinical trial (GliAvAx)

Autor: Bart Neyns, Julia Katharina Schwarze, Gil Awada, Laila Ben Salama, Jennifer De Cremer, Lydia Fischbuch, Laura Seynaeve, Stephanie Du Four, Anne-Marie Vanbinst, Alex Michotte, Hendrik Everaert, Anne Rogiers, Peter Theuns, Johnny Duerinck

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)

Background No treatment demonstrated to improve survival in patients with recurrent glioblastoma (rGB) in a randomized trial. Combining axitinib with the programmed cell death ligand 1 blocking monoclonal antibody avelumab may result in synergistic a

Externí odkaz: https://doaj.org/article/148c1424e10448fa9ffb5c151ec0bf59

Neurocognitive Function, Psychosocial Outcome, and Health-Related Quality of Life of the First-Generation Metastatic Melanoma Survivors Treated with Ipilimumab

Autor: Jennifer De Cremer, Julia Katharina Schwarze, Christophe Leys, Jan L. Bernheim, Anne Rogiers, Adrian Schembri, Gil Awada, Justine Lauwyck, Bart Neyns, Mark De Ridder, Peter Theuns, Paul Maruff

Publikováno v: JOURNAL OF IMMUNOLOGY RESEARCH
Journal of Immunology Research, 2020
Journal of Immunology Research
Journal of Immunology Research, Vol 2020 (2020)

Purpose. To assess neurocognitive function (NCF), psychosocial outcome, health-related quality of life (HRQoL), and long-term effects of immune-related adverse events (irAE) on metastatic melanoma survivors treated with ipilimumab (IPI). Methods. Mel

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e4b49d53433f064b7f0ca15c8064cbab
https://biblio.vub.ac.be/vubir/neurocognitive-function-psychosocial-outcome-and-healthrelated-quality-of-life-of-the-firstgeneration-metastatic-melanoma-survivors-treated-with-ipilimumab(191c29b1-87cb-439b-a6fb-3ca5b1fc4257).html

SCDT-13. PHASE I CLINICAL TRIAL ON SYSTEMIC PD-1 BLOCKADE IN COMBINATION WITH DIRECT INTRA-TUMORAL INJECTION OF CTLA-4/PD-1 IMMUNE CHECKPOINT INHIBITION FOLLOWING RESECTION OF RECURRENT GLIOBLASTOMA

Autor: Anne Rogiers, Pieter Theuns, Hendrik Everaert, Bart Neyns, Johnny Duerinck, Anne Van Binst, Stephanie Du Four, Jennifer De Cremer, Lailia Ben Salama

Recurrent glioblastoma is a devastating disease for which no treatment has demonstrated to improve overall survival in a randomized clinical trial. Anti-tumor Cytolytic T-cell (CTL) activity is suppressed by the CTLA4 and PD-1 immune-checkpoint recep

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15018e01728218df26e6a63a50e42ab7
https://europepmc.org/articles/PMC5692518/

Psychosocial outcome and health-related quality of life (HRQoL) in advanced melanoma survivors

Autor: Peter Theuns, Jan L. Bernheim, Laila Ben Salama, Jennifer De Cremer, Bart Neyns, Anne Rogiers, Mark De Ridder

Publikováno v: Journal of Clinical Oncology. 36:162-162

162 Background: An increasing proportion of advanced melanoma patients (pts), treated with immune checkpoint inhibitors and/or BRAF/MEK-inhibitors, achieve long-term survival. The traumatic experience of melanoma progression, which often involves the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::33c6127fee42a63cc1aa667bcc567166
https://doi.org/10.1200/jco.2018.36.7_suppl.162